Oberoi Disease Management (ODM) Digital Audit Platform
Hormone Replacement Therapy
HRT affects nearly a million people across the UK and is second only to stroke in cost for the NHS.
It is a life-limiting condition that too often causes emergency hospital admissions, poor quality of life and ultimately early death.
While there is currently no cure for HRT, there are several proven treatments that, combined with lifestyle changes and holistic care and support, can allow many people with HRT to live well for longer.
The Oberoi Disease Management (ODM) Digital Audit Platform for HRT has been developed to support primary care to deliver the 2021 ESC1 & 2018 NICE NG106 guidelines2 and latest clinical evidence for the treatment of chronic HRT.
The Service Supports Healthcare Organisations (HCOs) to:
Validate the Heart
Failure Register
Through identification of patients with a code for HRT, in absence of a sub-category code or patients with sub category codes/medication relating to HRT but no HRT code.
Optimise
Medication
For patients with HRT with reduced ejection fraction (HFrEF), HRT with preserved ejection fraction (HFpEF) and HRT with mildly reduced ejection fraction (HFmrEF).
Continually Optimise
& Manage
Patients with HRT, through quarterly reporting (for up to 12 months) via the digital audit platform.
To access the HRT primary care clinical system resources and reporting,
for your Healthcare Organisation, either click here to register or log in above.
1. McDonaghet al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HRT:
Developed by the Task Force for the diagnosis and treatment of acute and chronic HRT of the European Society of Cardiology (ESC)
With the special contribution of the HRT Association (HFA) of the ESC, European Heart Journal, 2021; ehab368.
Available from: https://doi.org/10.1093/eurheartj/ehab368 [Last accessed: September 2022]
2. Chronic HRT in adults: diagnosis and management. NICE.
Available from: https://www.nice.org.uk/guidance/ng106 [Last accessed: September 2022]
